IDYA

25.5602.33%
JL

Jeffrey L. Stein

Independent Director

Dr. Jeffrey L. Stein, Ph.D., also known as Jeff, had been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014 until January 7, 2026. Dr. Stein served as Principal Financial Officer at Cidara Therapeutics, Inc. since July 09, 2021 until August 2021. Dr. Stein serves as Principal Scientist of Verenium Corporation. He is Scientific Advisor of Spero Therapeutics, Inc. Dr. Stein served as Senior Vice President of Educational Strategy at MedCases, LLC. Dr. Stein served as a Principal Scientist of BASF Enzymes LLC. He serves as a Faculty Research Associate at UC San Diego's Center for Marine Biotechnology and Biomedicine and in the Marine Biology Research Division of Scripps Institution of Oceanography. Dr. Stein was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein served as the President and Chief Executive Officer of Trius Therapeutics Inc. since February 2007. From 2005 to 2010, he was a Venture Partner at Sofinnova Ventures, Inc. He joined the Sofinnova Ventures, Inc. in May 2005 as a Kauffman Fellow at the Sofinnova Ventures till 2007 and was a part of the life science team. He works with Sofinnova's life science investment team to identify San Diego-based investment opportunities in the area of biopharmaceutical clinical development and advises the firm's life science portfolio companies on clinical and business matters. He has held senior scientific and management positions in the biopharmaceutical industry. From 1999 to 2005, Dr. Stein was the Founder and Chief Scientific Officer of Quorex Pharmaceuticals, Inc. from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005 and also served as its Executive Vice President. He served as a Principal Scientist and Head of the anti-infectives discovery team at Diversa Corporation. From 1995 to 1999, Dr. Stein was a scientist with the Diversa Corporation. From 1993 to 1995, he was a Principal Investigator at the Agouron Institute, where his laboratory developed techniques to clone and characterize microbial gene pathways. He serves on the Board of Rx3 Pharmaceuticals and Quorex. He has been an Independent Director of IDEAYA Biosciences, Inc. since October 2015. He had been an Independent Director of Paratek Pharmaceuticals, Inc. since October 30, 2014 until September 21, 2023 and served as its Lead Independent Director since December 08, 2022 until September 21, 2023. He served as an Executive Director of Trius Therapeutics, Inc. since 2005. He served as a Director of Quorex Pharmaceuticals, Inc. He served as Director of Venture Development at University of California - San Diego. He was also founding Chairman and President of the Antibiotics Working Group. Dr. Stein has also served as Director of Venture Development at UC San Diego from 2005 to 2006. He is considered an authority on the cloning and expression of microbial gene pathways and is a frequent invited lecturer on this topic at research and governmental institutions worldwide. he was a past Member of the National Research Counsel’s Task Group for the Limits of Organic Life in Planetary Systems, a Member of the President’s Panel on National Ocean Exploration Strategy and a past Member of the National Science Foundation’s Engineering Center Site Review Team. Among the various honors he has received is the Thomas Alva Edison Patent Award. Dr. Stein holds a Ph.D. in Biochemistry and Marine Biology from the University of California, San Diego. Dr. Stein conducted his postdoctoral research in bacterial genetics as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology. Dr. Stein obtained a B.S. in Marine Biology and an M.S. in Biology from California State University, Long Beach. He is Graduate Student Researcher Fellow at UCSD.

公司職務